The Protective Role of Interleukin-37 in Cardiovascular Diseases through Ferroptosis Modulation
Round 1
Reviewer 1 Report
Comments and Suggestions for Authors
|
Minor editing of English language required.
Author Response
Please see the attachment
Author Response File: Author Response.docx
Reviewer 2 Report
Comments and Suggestions for AuthorsThis was an interesting review of ferroptosis and the potential role of IL-37 in preventing ferroptotic cell death in cardiovascular disease. The figures were clear and the figure legends very helpful for the reader.
The review itself would benefit from focusing more on IL-37, ferroptosis particularly in CVD instead of presenting a very in depth review of ferroptosis in a wide variety of tissues.
Minor edits.
1. Line 71- change no enzymatic to non-enzymatc
2. Line 133- what is meant by six membrane epithelial cells?
3. line 135- just a look should be changed to this a brief overview ( More formal writing and less slangy)
4. Are any ferroptotic inhibitors used clinically? Used in CVD? If so add to the text.
5. line 199, spello out ACSL4 and LPCAT3
6.Page 12, there is alteration between the use of hepcidin and hamp. I would suggest sticking with hepcidin to be clear.
7. Line 359- "main protein for receptors" to "downstream mediators" or "direct targets"
8, 362 space is needed between Smad3 and knockdown
9. 377 TGFb has been defined you do not need to define again.
10. Line 398 was unclear to me. Please rewrite.
Comments on the Quality of English LanguageEnglish was fine
Author Response
Please see the attchment
Author Response File: Author Response.docx
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsAuthors respond adequately to previous comments and make changes accordingly. Interaction between Ferroptosis and CVDs may be discussed more. The paper is acceptable for publication.
Comments on the Quality of English LanguageMinor revision is required before final submission